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ASSOCIATION OF GAMMA GLUTAMYL TRANSFERASE 
LEVELS WITH ACUTE CORONARY SYNDROME AND 
CORRELATION WITH IN-HOSPITAL OUTCOME 
ABSTRACT 
 
BACKGROUND:  Although traditionally associated with alcoholic liver 
disease, recent studies have shown evidence of correlation between elevated 
Gamma-glutamyltransferase (GGT)  and atherosclerotic heart disease. This is 
said to be due to its role in the generation of reactive oxygen species in the 
presence of iron. It is independently correlated with conditions associated with 
increased atherosclerosis, such as obesity, elevated serum cholesterol, high 
blood pressure and myocardial infarction. It is also demonstrated that serum 
GGT activity is an independent risk factor for myocardial infarction and cardiac 
death in patients with coronary artery disease. 
AIM: To study the correlation between rise in GGT levels and different subsets 
of Acute Coronary Syndrome. To study the correlation between GGT and risk 
of Major Adverse Cardiovascular Events(MACE). 
MATERIALS AND METHODS: This is a cross sectional study conducted at 
Government Royapettah Hospital and patients admitted with Acute Coronary 
Syndrome in our ICU were selected. GGT levels were measured for all patients 
in a standardized manner and cases were observed for five days in the hospital 
for adverse events. This study was done for a time period between May 2013 to 
October 2013 and 75 patients with ACS were included. 
RESULTS AND OBSERVATIONS: Serum GGT levels were significantly 
elevated in both the STEMI and NSTEMI subsets but not in the unstable angina 
subset. The mean GGT value for patients who suffered complications is 90.22. 
The mean value for patients without MACE is a significantly less 46.44. There 
was also found to be correlation between GGT and presence of hypertension, 
LV dysfunction, total cholesterol and LDL levels.  
CONCLUSION: Gamma glutamyltransferase levels were significantly elevated 
above normal in patients presenting with acute coronary syndrome. GGT levels 
were independently correlated with STEMI and NSTEMI but had no correlation 
with unstable angina. There was a significant correlation between GGT levels 
and incidence of left ventricular systolic LV dysfunction. The mean value of 
GGT was significantly elevated in patients who suffered from major adverse 
cardiovascular events. Patients with significantly elevated GGT values may, in 
future, be referred for early invasive revascularization procedures like 
PCI/CABG. In conclusion, as concerns ischemic heart disease, GGT assay 
seems to have the features of a good prognostic marker with optimal sensitivity 
of the diagnostic assay and it helps improve our ability to predict adverse events 
in CAD. Further its prognostic impact can be utilized in risk stratification and 
the need for urgent therapeutic intervention. 
KEYWORDS: Gamma Glutamyl Transferase, Acute Coronary Syndrome, LDL 
oxidation, atherosclerotic plaque, MACE. 
 
 
                                                  INTRODUCTION 
 
 Sudden onset chest pain is one of the commonest causes for presentation 
to the hospital casualty. Even though acute onset chest pain is very often 
assumed to be acute coronary syndrome (ACS), after further workup only 15% 
to 25% of patients with acute chest pain have MI.
1,2
 The important diagnostic 
challenge  is to differentiate patients with ACS or other life-threatening 
conditions from patients with noncardiovascular, benign causes of chest pain. 
The diagnosis of ACS is overlooked in about 2% of patients, which can lead to 
negative consequences. The acute coronary syndromes constitute a range of 
heart diseases from unstable angina to ST elevation myocardial infarction. The 
basic pathophysiology is similar for the entire spectrum in the form of a 
thrombus overlying a plaque. The approach to treating all these diseases is 
fundamentally similar but with certain unique features depending on the type of 
acute coronary syndrome. Several recent advances, have enhanced the accuracy 
and efficiency of the evaluation of patients with acute chest pain, mainly owing 
to  better biomarkers of cardiac injury.
3
 
 
Cardiac markers are proteins released into the circulation when cardiac 
cells die. These are troponin I, troponin T, myoglobin and CK-MB . These 
cardiac markers play an essential role in diagnosing as well as stratifying acute 
coronary syndrome (ACS). A variety of molecules have been used to diagnose 
and prognosticate acute coronary syndromes ranging from LDH and myoglobin  
to creatine phosphokinase and troponins. The current management particulars 
are centered around the measurements of troponins which are both highly 
specific and sensitivity to acute cardiac insult. However the search is still 
ongoing for other molecules and enzymes which will help in assessing the 
severity of various forms of myocardial infarction. Stratification of ACS into 
high and low risk is imperative not only regarding the adequacy of treatment but 
also in avoiding unnecessary costs and inconvenience to the patient. 
Among the latest armamentarium of molecules being investigated for 
diagnosing and more importantly, prognosticating myocardial infarction is an 
enzyme called Gamma Glutamyl Transferase (GGT).
4
 Well recognised as a 
marker of alcohol induced liver injury, GGT has gained importance in recent 
years as a marker of acute cardiac injury and has shown correlation with a host 
of risk factors responsible for macrovascular diseases, primarily coronary artery 
disease. GGT shows promise as a new tool in the risk stratification of various 
types of acute myocardial infarction. 
 
 
 
 
 
REVIEW OF LITERATURE 
                
  HISTORY OF MYOCARDIAL INFARCTION 
 
Even though modern sedentary life style is unanimously blamed for the 
increasing prevalence of coronary artery disease, the latter seems to be as old as 
human civilization itself. In 2009, researchers discovered evidence of  
atherosclerosis  and narrowed arteries in Egyptian mummies four millennia old. 
It was attributed to their princely lifestyle, diet rich in fat. It is known that 
Leonardo Da Vinci, that pioneer of all sciences, investigated diseased coronary 
arteries in vagabonds, a full century before William Harvey even discovered 
cardiac circulation. Later, Friedrich Hoffmann (1660–1742), Cardiology head at 
the Halle University, astutely commented that coronary heart disease started in 
the “reduced passage of the blood within the coronary arteries.” Angina was a 
source of confusion to clinicians for the last two centuries. When first 
elaborated in 1768, it was suspected by clinicians of that day to have something 
to do with blood flow in the coronary arteries. 
William Osler (1849–1919) studied angina extensively, and was the earliest to 
call it a syndrome rather than a disease. James B. Herrick (1861–1954), an 
American cardiologist suggested that an indolent process of occlusion of the 
arteries in the heart could be the reason for angina. The 1900s mark a start of a 
period of increasing research in coronary artery disease. A group of doctors 
started the first “Association for the Prevention and Relief of Heart Disease” in 
New York City in 1915. Just a few years down the lane, doctors started using 
catheters to explore coronary arteries. The pioneers mainly responsible for this 
new technology were Egas Moniz (1874–1955) and physician Werner 
Forssman (1904–1979). This new investigation played a major role in correctly 
diagnosing coronary artery disease. However it was only following the initiation 
of the Framingham Heart Study in 1948 that the mystery behind CAD slowly 
started unraveling. In the 1970’s newer treatments were introduced in the form 
of bypass surgery and angioplasty for treating CAD. In the 1980s, stents began 
to be commonly used to open up narrowed arteries. The last two decades have 
opened up new vistas in the management of this serious disease. Therefore 
coronary artery disease is no longer a death sentence as a result of these latest 
advances in diagnosis and treatment 
 DEFINITION 
Acute coronary syndromes are defined based on the characteristics of three 
cardinal elements; history of typical angina, presence or absence of changes in 
ECG, and markers of cardiac injury. In certain exceptional cases, a diagnosis of 
MI can be rarely made even in the absence of the above mentioned criteria such 
as in the case of a past recorded history of coronary artery disease.
5
 
The pathologic diagnosis of myocardial infarction (MI) requires evidence of 
cardiac cell death as a result of compromised blood supply. ACS follows a 
range of clinical manifestations which follow the disturbance of an atheroma 
and formation of an overlying thrombus. A complete block in the vessel in the 
absence of collateral perfusion results in ST-segment elevation (STEMI) and a 
non occlusive thrombus leads to non-ST-segment elevation myocardial 
infarction (NSTEMI). The newer definition of MI divides it into five categories 
depending on the scenario in which it occurs.
6 
Revised Definition of Myocardial Infarction
 
Criteria for Acute, Evolving, or Recent MI 
Either of the following criteria satisfies the diagnosis for acute, evolving, or 
recent MI: 
1. Typical rise and/or fall of biochemical markers of myocardial necrosis with at 
least one of the following: 
a. Ischemic symptoms 
b. Development of pathologic Q waves in the ECG 
c. Electrocardiographic changes indicative of ischemia  
d. Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality 
2. Pathologic findings of an acute myocardial infarction 
 Criteria for Healing or Healed Myocardial Infarction 
Any one of the following criteria satisfies the diagnosis for healing or healed 
myocardial infarction: 
1. Development of new pathologic Q waves in serial ECGs.. 
2. Pathologic findings of a healed or healing infarction 
 
The contemporary approach to patients presenting with ischemic discomfort is 
to mostly assume that they are experiencing an acute coronary syndrome. The 
12-lead electrocardiogram (ECG) categorizes them into ST elevation and non 
ST elevation MI. 
The idea of acute coronary syndrome, which is based on a central 
pathological tenet, is invaluable in formulating treatment strategies.
7
 Cases 
coming with ST elevation are selected for reperfusion treatment either through 
device or pharmacological measures. ACS patients presenting with ecg changes 
other than ST elevation are not selected for reperfusion therapy but should be 
given medical drugs for countering ischemia, followed by PCI.
8
 However, 
antiplatelet and anticoagulant therapy is mandatory for both types. Hence, the 
electrocardiogram is invaluable in the approach and treatment of cases 
presenting with significant chest pain. 
9
 
DEFINITION OF UNSTABLE ANGINA AND NON ST ELEVATION MI 
“Unstable angina is defined as angina pectoris (or equivalent type of 
ischemic discomfort) with at least one of three characters: (1) occurring at rest 
(or minimal exertion) and usually lasting >20 minutes (if not interrupted by the 
administration of a nitrate or an analgesic); (2) being severe and usually 
described as frank pain; or (3) occurring with a crescendo pattern (i.e., pain that 
awakens the patient from sleep or that is usually more severe than 
previously)”.10 Around  two thirds of patients with unstable angina have 
evidence of myocardial cell death on the basis of elevated cardiac serum 
markers, such as cardiac-specific troponin T or I and creatine kinase isoenzyme 
(CK)–MB, and thus have a diagnosis of NSTEMI.  
A clinical classification of UA/NSTEMI 
11
 provides a useful means to 
stratify risk. Patients fall into three groups according to the clinical 
circumstances of the acute ischemic episode: 
 (1) Primary unstable angina caused by reductions in myocardial blood flow;  
(2) Secondary unstable angina (as a result of increased demand, as in anemia); 
and  
(3) Post-MI unstable angina.  
  
 
FIG-DEFINITION AND CLASSIFICATION OF UNSTABLE ANGINA 
 
This classification provides valuable prognostic information (with 
postinfarction angina at rest having the worst prognosis). 
EPIDEMIOLOGY 
 Cardiovascular disease (CVD) is accelerating fast to become one of the 
most important cause of mortality worldwide. In 2004, CVD caused about 30% 
of all deaths and 14% of all DALYs (disability adjusted life years) lost that 
year.
12 
The developing world is one apart of the  world that is worst hit by CVD  
13,14
. Increases in childhood obesity and physical inactivity are primarily 
responsible for the upsurge in cardiovascular mortality.
15,16 
Several studies in 
India have suggested a rising morbidity caused by CHD in this region. 
Approximately  31.8 million people are living with CHD in India alone,
17
  ten 
times more  than what it was  40 years ago. Additional evidence suggests that 
women are more likely than men to have CVD in India.
18
  
  Manifestations of coronary artery disease present themselves almost a 
decade earlier in the Indian population compared to the west.
19
 One half of the 
CVD deaths in India occur in people who fall below the seventh decade
 20
. By 
2001, CVD was responsible for 29% of all deaths and 14% of the 1.5 billion 
lost DALYs. 
21 
Countries belonging to the south east asian region have a greater number 
of diabetics than in their European and American counterparts. The maximum 
number of diabetics are housed in China and India.
22
 This can also account for 
the high burden of coronary artery disease and stroke in our country. 
 In 2006, Goyal and Yusuf
20
 concluded that the prevalence of diabetes 
mellitus was 11.8% in urban areas and 3.8% in rural areas . Similarly, IC Health 
showed that prevalence was 13% in the urban setup.
23
 According to the 
INTERHEART study, DM accounts for 11.8 of all the MI in the South East 
Asian region. 
19
  
Hypertension rates higher in its association with MI. In the Interheart 
study, hypertension was associated with 19.3% cases of MI.
19
  
Another risk factor gaining increasing importance is overweight and 
obesity. Other factors that contribute to coronary artery disease have also been 
noted by the Interheart study. Low intake of fruits and vegetables accounts for 
18.3% of MI, lack of exercise 27.1%, and lipids 58.7%. In total, a total of nine 
risk factors account for 89.4% of all causes of MI.
19
 
PATHOLOGY OF MYOCARDIAL INFARCTION 
Coronary atherosclerosis with overlying thrombus development is the cause for 
all MI.  As the atheroma progresses, a catastrophic change occurs over the 
plaque resulting in the formation of a thrombus on top .
24,25
 Some patients have 
a preexisting predilection for rupture of the plaque which is related to the 
oxidative status of the body.
26
 Plaque rupture releases molecules that encourage 
the activaton of platelets which contribute to the formation of thrombus. The 
resultant thrombus leads to an abrupt halt in blood supply and eventual myocyte 
death as a result of decreased supply of oxygen. 
 
 
 
 FIGURE- RUPTURE OF AN ATHEROMATOUS PLAQUE 
 PLAQUE FISSURING AND DISRUPTION.  
Once the plaque ruptures, a  variety of enzymes will be released which 
will breakdown the components  of the atheroma.
27,28
 Mast cells and 
macrophages which are chemotactically attracted to the plaque, release these 
proteinases. A variety of other factors like intraluminal pressure, vessel tone, 
and tachycardia act in synergy to bring about disruption. This happens at the so 
called ‘shoulder region of the plaque’, situated at the at the margin of the 
fibrous cap which is usually not affected by atherosclerosis.
29
 Usually, 
completely occlusive thrombi lead to infarction of the entire thickness of the 
ventricular wall and usually STEMI on ecg. Cases with ECG changes other than 
ST elevation are labeled as unstable angina or NSTEMI and they usually have 
an incomplete occlusion of the vessel; so called non occlusive thrombus. 
PATHOPHYSIOLOGY OF ST ELEVATION MYOCARDIAL INFARCTION 
On interruption of coronary flow, the volume of ventricular mass 
sustenanced by the artery shows signs of poor contraction. Four abnormal types 
of contraction develop in sequence:  
(1) Dyssynchrony—that is, adjacent segments contracting at different times 
 (2) Hypokinesis-reduced contraction; 
 (3) Akinesis- absence of contaction and 
 (4) Dyskinesis- abnormal expansion and systolic bulging  
  If a sufficient quantity of myocardium undergoes ischemic injury, LV 
pump function is compromised; cardiac output and stroke volume  fall
30
; and 
end-systolic volume rises. The degree to which end-systolic volume rises is the 
most  important factor deciding mortality following STEMI.
31
 In certain 
patients, a vicious circle of dilation ensues, causing further dilation. The degree 
of ventricular dilation depends on the size of the infarct, the amount of coronary 
stenosis and activation of the renin-angiotensin-aldosterone system (RAAS). It 
can be favorably modified by inhibitors of this system.
32
  
                             
 
Figure- pathophysiology of myocardial infarction 
 
If the infarcted area is more, LV function is severely depressed and the  
LV stroke volume falls,  filling pressures rise. This leads to a marked 
depression of aortic pressure and decreased coronary blood flow; this 
condition may worsen myocardial ischemia and thereby initiate a vicious 
circle. Worsening LV function also leads to a rising preload. Even though 
this compensates to a certain level the stroke volume, the ejection fraction 
is compromised in the process. The dilation of the left ventricle also 
increases ventricular afterload. This is because, in keeping with the 
Laplace’s law, the ventricle will have to generate a higher wall tension in 
response to the grossly dilated ventricle. This increased after load 
increases oxygen consumption in the myocytes and worsens the ischemic 
process. 
PATHOPHYSIOLOGY OF UNSTABLE ANGINA AND NSTEMI 
The pathophysiologic processes mainly responsible for the development of 
UA/NSTEMI 
33
 are: 
1. Ruptured atheromatous plaque with formation of a thrombus partially 
occluding it. 
 2. Non structural narrowing of the coronary vessels due spasm as a result of 
increased adrenergic activity. 
 3. Restenosis of coronary vessel after PCI or progressive atherosclerotic 
occlusion of lumen.  
4. UA as a result of inflammation. 
5. As a result of increased nutrition demands for instance, fever or anemia. This 
is labeled as secondary unstable angina. 
 
Platelets play a major role in the conversion of a stable plaque to a 
devastating lesion. Break in an atherosclerotic plaque often opens up the 
subendothelial matrix (e.g., collagen and tissue factor) to circulating blood. The 
subsequent mechanisms of adhesion, activation, degranulation, and platelet 
aggregation leads to the formation of a thrombus. 
 
 
FIG-Mechanisms of unstable angina 
 
  
 SECONDARY HEMOSTASIS.  
The coagulation system is subsequently activated as soon as the platelet 
plug is formed. Ultimately, the fibrin formed gets cross-linked and the clot is 
stabilized. 
        CLINICAL FEATURES OF MYOCARDIAL INFARCTION 
The most crucial element in the diagnosis of ACS is the history. The 
prodrome is usually characterized by chest discomfort, resembling classic 
angina pectoris, but it occurs at rest or with less activity than usual and can 
therefore be classified as unstable angina. The discomfort, usually long drawn, 
is described as crushing or compressing and the patient usually describes the 
pain as if some weight is placed on his chest. The pain is classically retrosternal 
in location, spreading to both sides of the anterior chest, more on the left. The 
pain of STEMI can also radiate to the shoulders, jaw or even the teeth with 
some rare cases even ending up in the dental OPD. The pain can be 
differentiated from stable angina keeping in mind its severity and prolonged 
duration.  Nausea and vomiting may occur, more commonly in patients with 
inferior STEMI .  
 
 
GENERAL APPEARANCE.  
Patients suffering STEMI often appear anxious and in considerable distress. 
They often massage or clutch their chests and frequently describe their pain 
with a clenched fist held against the sternum (the Levine sign). 
 
HEART RATE. 
  The heart rate can vary from a marked bradycardia in cases of inferior 
wall involvement, to a rapid regular or irregular tachycardia, depending on the 
underlying rhythm and degree of LV failure. 
Auscultation of the heart can be sometimes rewarding in discovering a 
third heart sound or rales in cases of heart failure or a new onset systolic 
murmur in case of a regurgitant mitral valve or a septal rupture.
34 
LABARATORY INVESTIGATIONS 
ELECTROCARDIOGRAPHY 
A majority of patients presenting with ACS have a host of serial 
electrocardiographic changes. Observation of the different leads involved can 
also give a clue as to which artery is involved.
9
 The location of the infarction, 
the duration of the QRS complex and the extent of ST elevation have direct 
correlation with adverse events in MI. Analyzing the ecg following treatment 
can help in assessing success of reperfusion strategies. Electrocardiographic ST-
segment resolution strongly predicts outcome in STEMI patients but is a better 
predictor of an occluded artery than of a patent infarct-related artery.
35
ST-
segment resolution in combination with cardiac biomarkers (e.g., troponins, 
natriuretic peptides) provides powerful prognostic information early in the 
management of STEMI patients.
36
 
 
SERUM MARKERS OF CARDIAC DAMAGE 
With the advent of serum cardiac markers, clinicians are able to identify 
cases of MI which have gone undiagnosed previously.
37
 
However despite its importance, care should be taken that the initiation of 
treatment does not depend on the cardiac marker assay. Because there is an 
urgency for reperfusion in STEMI, the 12-lead ECG is more than adequate to 
initiate treatment. 
Following an ischemic attack the membranes of the myocyte become 
increasingly permeable, leading to a leak of intracellular molecules into the 
systemic circulation.
38,39
 How and when these macromolecules are released into 
blood depend on multiple factors, including molecular weight, local blood flow, 
and rate of elimination.
40
 
 
Creatine Kinase  
Serum CK activity rises within 5 to 8 hours after myocardial infarction and 
declines to normal within 2 to 3 days . Usually the peak levels of CK occur at 
about 24 hours although it can occur earlier as a result of reperfusion 
therapies.Although serum CK concentration can accurately predict STEMI, 
plenty of false positives can occur with alcohol intoxication, muscle injury, 
pulmonary embolism and seizures. 
41
Three isoenzymes of CK exist (MM, BB, 
and MB). Rather than depending on a single value, the rise and progression of 
repeated values should be observed. 
CARDIAC SPECIFIC TROPONINS 
Three subunits make up the troponin complex. Troponin C binds to 
calcium, troponin I (TnI), binds to actin and prevents actin-myosin interactions, 
and troponin T (TnT), binds to tropomyosin. Following myocyte death, cTnI 
and cTnT gets released from the cytosolic pool, followed by release from the 
structural (myofilament-bound) pool. One of the most important aspects in 
diagnosing MI is the estimation of Troponins.
42
 For  the Troponins, there is no 
fixed value above which it becomes abnormal. Rather, a recording above that of 
99% of a control group is significant.
 42
 
Whereas when CK-MB usually increases ten times the normal value, cTnT and 
cTnI typically increase more than 20 times above its normal range. The 
troponins can remain elevated in blood for 10 to 14 days and this can be made 
use of in the late diagnosis of MI. Therefore it has become imperative to 
measure troponins in all cases of suspected ACS 
OTHER LABORATORY FINDINGS 
Hematologic Findings.   
The neutrophil count rises 2 to 3 hours following the episode of MI, 
reaches its peak level within 48 hours and becomes normal within a week. An 
epidemiological relationship has been discovered between high WBC count, 
particularly neutrophil count and adverse outcomes in ACS.
43
 
High CRP levels have also been associated with a higher incidence of heart 
failure in STEMI and a higher grade of occlusion in the artery.
44
 
IMAGING  
X-RAY 
Prominent pulmonary markings can be reflective of the raised LV end 
diastolic pressure. The amount of congestion and the degree of cardiomegaly on 
the chest film can be useful in predicting the patients who will be more prone 
for cardiac failure. 
 
 
ECHOCARDIOGRAPHY 
Echocardiography can be done for ACS patients in the coronary care unit 
or even in the emergency department before admission. 
45
 In patients with chest 
pain compatible with MI but with a nondiagnostic ECG, the finding of a distinct 
regional wall motion abnormality on echocardiography can be helpful 
diagnostically because it supports the diagnosis of myocardial ischemia. LV 
function estimated from echocardiograms correlates well with measurements 
from angiograms and is useful in establishing prognosis after MI.
45
  
 
ESTIMATION OF INFARCT SIZE  
The sum of ST-segment elevations measured from multiple precordial 
leads correlates with the extent of myocardial injury in patients with anterior 
MI.
46
 Measuring a cardiac-specific troponin level several days after STEMI, 
even in cases of successful reperfusion, may provide a reliable estimate of 
infarct size, because such late troponin measurements reflect delayed release 
from the myofilament-bound pool in damaged myocytes.
47
 
TREATMENT OF STEMI 
THE 12 lead ECG has to be promptly obtained for any case presenting 
with symptoms suggestive of  myocardial infarction. If the initial reading shows 
ST-segment elevation of 1 mm or more in at least two contiguous leads or a 
new or presumably new left bundle branch block, the patient should be prepared 
immediately for a reperfusion strategy. Patients with an initial 
electrocardiographic reading that reveals new or presumably new ST-segment 
depression and/or T wave inversion, although not considered candidates for 
fibrinolytic therapy, should be treated as though they are suffering from 
NSTEMI or unstable angina (a distinction to be made subsequently after 
scrutiny of serial ECGs and cardiac biomarker measurements; 
GENERAL TREATMENT MEASURES  
Aspirin  
Aspirin is effective across the entire spectrum of acute coronary 
syndromes and forms part of the initial management strategy for patients with 
suspected STEMI . An optimum dose of 162 to 325 mg should be administered 
acutely in the emergency department.
7
 
Control of Cardiac Pain  
One of the primary aims in management following the assessment of 
hemodynamic stability is the control of pain. Control of cardiac pain typically 
uses a combination of nitrates, analgesics (e.g., morphine), oxygen, and in 
appropriately selected patients, beta-adrenergic blocking agents. Beta blockers 
relieve ischemic pain, reduce the need for analgesics in many patients, and 
reduce infarct size and life-threatening arrhythmias. Avoiding early intravenous 
beta blockade in patients presenting in Killip class II or higher is important, 
however, because of the risk of precipitating cardiogenic shock.
48
 
Limitation of infarct size 
The prognosis of MI depends on the amount of myocardium that is 
salvaged. Patients who succumb from cardiogenic shock generally exhibit a 
single massive infarct or a small to moderate-sized infarct superimposed on 
multiple prior infarctions.
49
 Patients who survive major infarcts can develop left 
ventricular dysfunction and the long-term mortality rate is higher than for 
survivors with small infarcts, who have lesser chances of hemodynamic 
instability.
50
 
Even though a lot of novel efforts are being attempted to limit the size of 
the infarct, early reperfusion remains the most useful in that aspect. 
 Reperfusion Therapy 
GENERAL CONCEPTS.  
Timely reperfusion of injured myocardium represents the most efficient 
way of restoring the balance between myocardial oxygen supply and 
demand.
51,52
 The amount of myocardium salvaged depends on the time interval 
between the event and reperfusion.
53,54
. Even though the efficiency of 
reperfusion strategies wane with time, sometimes even late reperfusion of 
stenosed infarct arteries may restore contraction in hibernating myocardium.
55
 
Fibrinolysis  
Fibrinolysis recanalizes thrombotic occlusion associated with STEMI, 
and restoration of coronary flow reduces infarct size and improves myocardial 
function and survival over the short and the long term.
56, 57
 
A total of nine trials have been conducted to study the efficacy of 
reperfusion using fibrinolytic methods. The results showed an 18% reduction in 
short-term mortality, and as much as a 25% reduction in mortality for the subset 
of 45,000 patients with ST-segment elevation or bundle branch block. 
CONTRAINDICATIONS FOR FIBRINOLYSIS 
 
 Figure COMPARISON OF DIFFERENT FIBRINOLYTIC AGENTS 
Complications of Fibrinolytic Therapy.  
The most frequent complications of fibrinolysis are bleeding from 
mucosal surfaces. Though they are usually minor bleeds, significant bleeding 
can sometimes occur especially for patients undergoing catheter related 
procedures.
58
 Cerebral hemorrhage is a rare but feared complication. 
Catheter-Based Reperfusion Strategies 
The diseased artery can also be opened up by a catheter-based strategy. 
This approach has now transformed from passage of a balloon catheter over a 
guidewire to include potent antiplatelet therapy (intravenous glycoprotein [GP] 
IIb/IIIa inhibitors and P2Y12adenosine diphosphate [ADP] antagonists), 
coronary stents, and thrombectomy.
7
 When PCI is used in lieu of fibrinolytic 
therapy, it is referred to as primary PCI. A PCI performed after a failed attempt 
at thrombolysis is called a rescue PCI. A strategy of routine delayed 
angiography and PCI after successful fibrinolytic therapy may also be 
considered for patients who are not at high risk.
59,60
  
Surgical management 
  STEMI patients are currently referred for coronary artery bypass grafting 
(CABG) for one of the following indications: patient is persistently 
symptomatic following fibrinolysis or PCI, high-risk coronary anatomy (e.g., 
left main stenosis or more than two vessel involvement) discovered at 
catheterization, or STEMI complicated by ventricular septal rupture or severe 
mitral regurgitation caused by papillary muscle dysfunction.  
ANTICOAGULANT THERAPY.  
Apart from its role in further progression of the clot, heparin can help 
prevent complications like DVT and pulmonary embolism. For every 1000 
patients treated with heparin compared with aspirin alone, there are five fewer 
deaths (P = 0.03) and three fewer recurrent infarctions (P = 0.04), at the 
expense of three more major bleeds (P = 0.001).
61
 
The usual mandate is to continue heparin for atleast 48 hours following 
fibrinolysis  and to maintain an activated partial thromboplastin time (aPTT) 
target of 1.5 to 2 times that of control.
7
 
Heparin may sometimes cause thrombocytopenia through immunological 
mechanisms but this occurs only in around 2% of patients.
62
 Bleeding is the 
most serious complication of MI, especially intracranial hemorrhage, when 
fibrinolytic agents are prescribed.
63
  
Low-Molecular-Weight Heparins  
An alternative for unfractionated heparin is low molecular weight 
heparin. LMWH decreases the incidence of reinfarctions, recurrent artery 
stenosis and repeated episodes of angina significantly when compared to 
heparin.
64
. The primary outcomes of mortality in the CREATE trial were 
comparatively better in patients treated with LMWH.
65
 
FactorXa antagonists.  
The OASIS-6 trial evaluated the specific factor Xa antagonist 
fondaparinux (2.5 mg subcutaneously) in 12,092 patients with STEMI.
66
 It 
showed better results compared to placebo but was similar in efficacy profile to 
heparin. 
ANTIPLATELET THERAPY.  
Following plaque rupture, platelets play an important role in formation of 
thrombus.
67
 In patients presenting acutely with STEMI, antiplatelet therapy 
reduces the composite endpoint of death and recurrent infarction.The  
CLARITY-TIMI 28 trial showed that the addition of  the P2Y12 inhibitor 
clopidogrel alongside treatment with aspirin to STEMI patients younger than 75 
years of age who received fibrinolytic therapy reduced the risk of clinical events 
(death, reinfarction, stroke) and reocclusion of a successfully reperfused infarct 
artery .
68
 Non enteric coated aspirin should be given as a bolus dose followed  
by low doses as maintenance to minimize risk of bleeding. When primary PCI is 
the mode of reperfusion therapy, an oral loading dose of 300 to 600 mg of 
clopidogrel before stent implantation is an established alternative.
69
 
BETA BLOCKERS.  
Betablockers have benefits that are present at the time of presentation as 
well as those that are life long. There is a 13% reduction in all-cause mortality 
(7 lives saved/1000 patients treated), 22% reduction in reinfarction (5 fewer 
events/1000 patients treated), and 15% reduction in ventricular fibrillation or 
cardiac arrest (5 fewer events/1000 patients treated). 
 INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM 
(RAAS).  
RAAS inhibitors, apart from having a favourable impact on ventricular 
remodeling, improves hemodynamics and reduces incidence of heart failure. 
Studies show that chronic administration of ACE inhibitors after a STEMI 
reduces ischemic events, including recurrent infarction and the need for 
PCI/CABG.
70
 
Aldosterone blockade is another pharmacologic strategy for inhibition of the 
RAAS.
71
  
Hemodynamic Disturbances 
Left Ventricular Failure 
Left ventricular dysfunction is the single most important predictor of 
mortality following STEMI.
72,73
 In patients with STEMI, systolic dysfunction 
alone, or both systolic and diastolic dysfunction can occur. 
 
Cardiogenic Shock 
The most severe culmination of left ventricular failure is cardiogenic 
shock, the incidence of which is around 5% to 8%. This low-output state is 
characterized by low stroke volume, high ventricular filling pressures, systemic 
hypotension, and evidence of vital organ hypoperfusion . 
 Figure-complications of acute coronary syndrome 
 
Mechanical Causes of Heart Failure  
Free wall rupture. The most dramatic complications of STEMI are those 
that involve tearing or rupture of acutely infarcted tissue leading to immediate 
hemodynamic compromise. 
 
RUPTURE OF THE INTERVENTRICULAR SEPTUM. 
 Risk factors for this feared complication are increased age, presence of 
hypertension, anterior wall MI and late fibrinolysis.
74
 Rupture of the 
interventricular septum almost always results in hemodynamic instability and 
confers a high 30-day mortality. 
 RUPTURE OF A PAPILLARY MUSCLE.  
Papillary muscle rupture can occur as a rare but often fatal complication 
of transmural MI.
75,76 
ARRYTHMIAS 
Arrhythmias can complicate the course of patients with ACS. They can 
either be bradyarrythmias or tachyarrythmias. Bradyarrythmias may be in the 
form of sinus bradycardia commonly seen in posterior and inferior infarctions 
or AV nodal blocks. Tachyarrythmias can range from benign ventricular 
premature depolarizations to life threatening ventricular tachycardia and 
ventricular fibrillation . 
Dressler Syndrome 
Also known as the postmyocardial infarction syndrome, Dressler syn-
drome presents usually with malaise, fever, pericardial discomfort, leukocytosis, 
an elevated sedimentation rate, and a pericardial effusion. 
Left ventricular aneurysm. 
  True left ventricular aneurysms probably develop in less than 5% of all 
patients with STEMI and perhaps somewhat more frequently in patients with 
transmural infarction (especially anterior).
77
 
MANAGEMENT OF UNSTABLE ANGINA/NSTEMI 
Electrocardiography  
Around 50% of patients of NSTEMI/UA present with ST depression (or 
transient ST elevation) and T wave changes 
78
. ST segment deviation of   ≥0.1 
mV, or even 0.05 mV in the presence of a preceding normal ecg is sufficient to 
bring about a diagnosis of NSTEMI/UA.
78
 Even transient ST elevation can 
occur in around 10% of cases, reflective of a higher rate of future ischemic 
events. T wave changes are sensitive but not specific for acute ischemia unless 
they are marked (>0.3 mV). 
Among patients presenting with symptoms consistent with UA/NSTEMI, 
elevations of cardiac markers (i.e., CK-MB, Troponin T or I) identify patients 
with the diagnosis of NSTEMI. With the use of Troponins, which are more 
sensitive than CK-MB, a greater percentage of patients are classified as having 
NSTEMI, which is associated with a worse prognosis.
79
 
 
 
Methods of Risk Stratification  
High-Risk Clinical Subgroups  
According to the clinical classification of unstable angina, there are 
certain subsets prone for increased mortality, such as secondary unstable angina, 
recurrent rest pain, post-MI unstable angina.
80
 Also, those patients with 
comorbidities like diabetes, hypertension and peripheral vascular disease are at 
a higher risk for hemodynamic complications.
81
 Similar to STEMI, patients with 
UA/NSTEMI who present with evidence of congestive heart failure (Killip class 
≥II) also have an increased risk of death. 
 
FIG-CLINICAL INDICATORS OF INCREASED RISK IN UA/NSTEMI 
Medical Therapy  
General Measures  
Patients with UA/NSTEMI at medium or high risk should be admitted to 
an intensive (cardiac) or intermediate care unit. The general principles of 
treatment are similar to that of STEMI, with obtaining adequate pain relief 
having prime importance. 
BETA BLOCKERS.  
Early placebo-controlled trials in UA/NSTEMI demonstrated the benefit 
of beta blockers in reducing reinfarct or recurrent ischemia.
82
 In patients with 
acute MI (both STEMI and NSTEMI), beta blockers have also been shown to 
reduce reinfarction and ventricular fibrillation.  
Aspirin (ASA)  
  Several trials have demonstrated clear beneficial effects of ASA in 
patients with UA/NSTEMI similar ro its role in STEMI.
83 
ADP ANTAGONISTS  
Thienopyridines 
These agents (ticlopidine, clopidogrel, and prasugrel)  inhibit platelet 
aggregation by inhibiting irreversibly the binding of adenosine diphosphate 
(ADP) to platelet P2Y12 receptors. The addition of clopidogrel to aspirin was 
studied in the CURE trial of 12,562 patients with UA/NSTEMI.
84
 Clopidogrel 
combined with aspirin, conferred a 20% reduction in cardiac death and re 
infarct with aspirin alone, in all patients with UA/ NSTEMI. 
Prasugrel.  
This thienopyridine, like ticlopidine or clopidogrel, is a prodrug whose 
active metabolite is an irreversible inhibitor of the platelet P2Y12 receptor, and 
thereby of platelet aggregation.  The TRITON-TIMI trial compared between 
prasugrel and clopidogrel. The primary efficacy endpoint (cardiovascular death, 
MI, and stroke) was reduced significantly by 19% in patients treated with 
prasugrel with slightly increased rates of non-fatal bleeding.
85
 
Ticagrelor is a reversible blocker of the P2Y12 platelet receptor that acts 
directly on the platelet.
86,87 
The PLATO trial showed the superiority of 
ticagrelor in reducing composite mortality when compared to clopidogrel.
88
 
 GLYCOPROTEIN IIb/IIIa INHIBITORS.  
These drugs block the final common pathway of platelet aggregation, the 
fibrinogen-mediated cross-linkage of platelets. Abciximab, eptifibatide and 
tirofiban are the agents present in this class. The use of these agents have been 
associated with a 9% reduction in composite mortality in patients presenting 
with NSTEMI/UA.
89
 The benefit of GP IIb/IIIa inhibition appears to be 
proportionately elevated in patients presenting with a higher risk in mortality, 
such as diabetics and those with gross ST segment deviations.
90,91
 
HEPARIN.   
The use of unfractionated heparin has been a cornerstone of therapy for 
patients with UA/NSTEMI.
92
 The addition of heparin to aspirin reduced 
mortality by 33% when compared to using aspirin alone.
93
 Further the use of 
LMWH, when added to ASA, has proved to be even more effective, leading to a 
66% reduction in death or MI.
93
 Early trials with enoxaparin showed a 20% 
reduction in death, MI, or recurrent ischemia compared with UFH.
94
  
FONDAPARINUX  
The OASIS-5 trial compared Fondaparinux was compared with LMWH 
in the OASIS-5 trial in 20,078 patients with high-risk UA/NSTEMI. Its 
performance was non-inferior to enoxaparin for the first nine days.
65,66
  
However, the rates of bleeding episodes were reduced almost by half in patients 
treated with fondaparinux. Thus, fondaparinux is a credible alternative to 
heparin for patients with UA/NSTEMI. 
 
 
 
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND 
ANGIOTENSIN RECEPTOR BLOCKERS. 
 Large trials have shown a 0.5% absolute mortality benefit of early 
(initiated within 24 hours) angiotensin-converting enzyme (ACE) inhibitor 
therapy in patients with acute MI.
95
  
LIPID-LOWERING THERAPY.  
Long-term treatment with lipid-lowering therapy, especially with statins, 
has shown benefit in patients after acute MI and UA/NSTEMI .
96
 
 
Treatment Strategies and Interventions 
There are two main approaches to using invasive revascularization in 
UA/NSTEMI: (1) an early invasive strategy, which involves an initial 
catheterization followed by PCI/CABG or medical therapy based on the 
angiography  and (2) a conservative approach, with initial medical management 
and catheterization at a later stage for patients who give symptoms of recurrent 
ischemia. To date, the efficacy of these strategies have been studied in 10 
randomized trials. Of these, six trials have shown overwhelming benefit of an 
early invasive therapy. 
97-99
 
Therefore, as a result of these trials an early invasive strategy is 
recommended at present in patients with UA/NSTEMI who have ST-segment 
changes or positive cardiac markers on admission. Hemodynamic instability and 
symptoms of recurrent ischemia are also indications for an early invasive 
strategy. An early invasive strategy is also advised in patients who present with 
UA/NSTEMI within 6 months of a prior PCI and in whom restenosis may be 
the cause. An early invasive approach is also indicated in patients with 
UA/NSTEMI with prior CABG. 
CARDIAC BIOMARKERS AND THEIR ROLE IN THE RISK 
STRATIFICATION OF ACS 
Markers of Myocyte Necrosis  
Just as STEMI patients have high rates of mortality, patients with 
NSTEMI, having elevated values of biomarkers of necrosis (CK-MB or 
troponin), perform poorly when compared to unstable angina patients.
100
 
Beyond just troponin positivity, even increasing values of troponins can be 
helpful in gauging the severity of the episode.
101
 However, in many studies, a 
greater risk of MI (or recurrent MI) was observed even with mild elevations of 
positive troponins. 
C-Reactive Protein and Other Markers of Inflammation  
There is an increased burden of death and MI in patients with high values 
of CRP at the time of presentation. Being an acute phase reactant, it is elevated 
by MI, with or without ST-segment elevation. So CRP is elevated five times 
more in ACS patients than normal.
102
 Among patients with negative Troponin I, 
CRP can discriminate between high- and low-risk groups. When both CRP and 
Troponin T are used, mortality can be stratified from 0.4% for patients with 
both markers negative, to 4.7% if either CRP or Troponin is positive, to 9.1% if 
both are positive.
103
 CRP measured after stabilization post-ACS strongly 
predicts outcome after 3 to 12 months.
104
 
 
Figure EMERGING MARKERS IN ACS AND THEIR UNDERLYING MECHANISMS 
 
Study of other inflammatory markers has offered consistent evidence of 
an association between systemic inflammation and recurrent adverse events, 
including serum amyloid A, monocyte chemoattractant protein and interleukin-
6. 
 Neopterin, a molecule related to monocyte activation, predicts long term 
outcomes in MI independently.
105
 Elevated levels of this inflammatory 
biomarker (as well as of CRP) have been found to be reduced by high doses of 
statins. These studies, taken together, indicate that inflammation relates to 
patient instability and to an increased risk of recurrent cardiac events. 
White Blood Cell Count 
This is an even simpler, convenient but nonspecific marker of 
inflammation. Several studies of have shown that high leukocyte count is 
associated with an increased risk of mortality and re infarct.  
Myeloperoxidase.  
(MPO) is a heme protein released during degranulation of neutrophils and 
monocytes during the inflammatory cascade. High MPO levels positively 
correlate with recurrent episodes of ischemia.
106,107
  
Natriuretic Peptides (BNPand NT-proBNP).  
B-type natriuretic peptide (BNP) is a neurohormone that gets released 
from the myocytes as a result of increased wall stress. Apart from its role in 
diagnosing heart failure, BNP has an emerging role in the prognostication of 
ACS. Studies have revealed that in NSTEMI/UA patients, higher levels of BNP 
correlated with increased rates of death and hemodynamic complications.
108-110
 
Creatinine.   
The use of creatinine or the measurement of creatinine clearance is 
another simple  marker for predicting adverse effects in ACS.
111
 The risk of 
impaired renal function appears to be independent of other standard risk factors.  
Glucose.  
In both diabetics and non diabetics, higher values of glucose or HbA1c 
correlated with higher rate of complications in patients presenting with MI.
112
 A 
synergistic relationship between hyperglycemia and inflammation has also been 
described.
113
 
Thrombus Precursor Protein 
This soluble fibrin polymer is a precursor to the formation of insoluble 
fibrin that may be increased in patients with acute MI. A positive correlation 
between thrombus precursor protein levels and the rates of adverse clinical 
outcomes in ACS has been observed.
114
 
 
GAMMA GLUTAMYL TRANSFERASE AND ITS ROLE IN THE 
MANAGEMENT OF ACUTE CORONORY SYNDROME 
Gamma glutamyl transferase is familiar as a serum investigation used in 
the diagnosis of alcoholic liver disease. However, in recent times it is being 
studied for its role in cardiovascular diseases with the underlying pathology of 
atherosclerosis. It is also being studied as a marker of severity of atherosclerotic 
or oxidative burden. This has practical implications in so far as it can help in 
selecting patients with higher risk for mortality.
115
 
The basic pathophysiology behind the various manifestations of 
myocardial infarction is inflammation.
116 
Therefore clinicians and 
epidemiologists have always been in the quest for ideal markers of 
inflammation with particular reference to ACS. However most of these markers 
are not commonly available or are too expensive. GGT is one of the promising 
enzymes being studied for its role in assessing the burden of inflammation. 
Gamma-glutamyltransferase (GGT) is an enzyme involved in the constant 
supply of  glutathione in the cell. It is involved biochemically in the breakdown 
of glutathione and in the process, recollects component amino acids to recycle 
glutathione (Fig. 1A). Thus this cellular enzyme ensures the constant 
regeneration of glutathione in the cell which in turn is responsible for multiple 
anti oxidant reactions.
117
However, recently in a plot twist, studies are providing 
increasing evidence that GGT can sometimes work against the cell by 
increasing the oxidative burden. This function materializes only in selected 
conditions, the most important of which is the proximity of transition elements 
like iron. This effect of GGT seems to occur when GGT is expressed in the 
presence of iron or other transition metals. When iron and other metals comes in 
concert with GGT, they get reduced ;and the electrons which get released in the 
process, bind to O2 molecules and make them reactive.
118
 In essence, an 
enzyme usually involved in cellular protective reactions can sometimes cause 
oxidative damage to the cell.
119-121
 
 
 
1).  (A) GGT in its normal role in breaking down and regenerating 
glutathione stores. 
 (B) GGT causing reduction of iron followed by superoxide formation. 
 
In other studies, GGT has been observed to be associated with raised 
levels of certain markers of oxidative injury. One such groups of molecules are 
called isoprostanes. 
122,123
 It has also been proven that the atheromatous lesion is 
rich in free iron and this can act in a permissive manner to aid the oxidant 
effects of GGT.
124 
One of the reasons behind the progression of an atheroma has 
been observed to be due to oxidation of LDL molecules by superoxide ions 
formed as a result of GGT activity.
125-128
 Hence there is increasing evidence 
piling up relating GGT and atherosclerotic disease processes. GGT is proving to 
be an important marker to efficiently stratify patients presenting with coronary 
artery disease as high risk or low risk.
129
 
Large volume studies have also been conducted to assess the relation 
between traditional risk factors for atherosclerosis and GGT. These studies have 
shown a strong positive correlation. Some of the features significantly 
associated with GGT were elevated low density and total cholesterol, poor 
glycemic control and male sex.
130
  Additionally one interesting association was 
between diets rich in meat and GGT.
 131,132
 This was possibly owing to the 
higher content of heme iron in meats. Further studies are probably warranted to 
study permissive effects of iron and GGT in the pathogenesis of 
atherosclerosis.
133 
GGT-AN EMERGING MARKER IN ATHEROSCLEROTIC HEART 
DISEASE. 
Even though GGT is traditionally being used for its role in gauging 
hepatic disease related to alcohol, recent studies reveal an important role in 
atherosclerotic heart disease.
134
 
Apart from analytical studies, histological reports have also corroborated 
this relationship. Microscopic studies of atheromatous lesions have shown 
increased amount of gammaglutamyl transferase activity in its basal layers. 
Also, activated macrophages with increased GGT activity were found to be 
associated with low density lipoprotein. 
Recently a subset of patients who survived acute coronary syndromes was 
evaluated for association between GGT and LDL in the blood. 
135,136
 Molecular 
studies revealed the close physical relationship between GGT and LDL enzyme. 
This is thought to be due to the peculiar biochemical organization of GGT 
which permits it to bind to low density lipoprotein. These studies help in 
incriminating GGT in its role in plaque development or rupture. 
 
GGT AND CORONARY FLOW 
The invasive revascularization strategies make use of a catheter to 
remove the clot in a diseased artery. However, long term studies have revealed 
that even after the removal of the clot, the viability of the subjacent myocardium 
depends on the functioning of the microcirculation.
137
Hence, even though a 
vessel is deemed successfully cleared by angiography, the myocardium may 
still suffer necrosis as a result of a dysfunctional microcirculation. 
138
 It has been 
observed that this group of patients suffers from higher rates of complications in 
spite of normal flow in their arteries.
139
 
After much research into this phenomenon it was elucidated that these 
microcirculation defects are caused as a result of increased oxidative reactions 
at the cellular level. Keeping in mind the role played by GGT in oxidative 
reactions, studies were performed to correlate the GGT levels and level of 
perfusion in the myocardium following catheter intervention. The same studies 
showed a positive correlation between the two suggesting that the oxidative 
stress involved in disturbed microcirculation was at least partly owing to the 
elevated GGT load in the body.
140, 141  
Therefore patients presenting with higher levels of GGT should be 
anticipated for impaired myocardial salvage following invasive 
revascularization. Further studies will be required to assess whether a shortened 
door to catheter time has a role in reducing the oxidative damage to the 
myocardium.  
Hence, GGT seems to have the adequate characteristics of a valuable 
prognostic factor in MI. The prognostication achieved by this enzyme can be 
practically realized in the form of policy interventions such as early referral to 
higher centres or early revascularization. This in turn can go a long way in 
reducing cardiac mortality and morbidity.
142
The new role of this enzyme in 
oxidative reactions and atherosclerosis gives a fresh approach to our 
understanding of acute coronary syndrome. Further, if properly utilized, GGT 
can also be used in the risk scoring and treatment of MI. 
 
 
 
 
 
 
 
 
 
 
 
 
 AIMS AND OBJECTIVES OF THE STUDY 
 
 
1. To determine the frequency of raised serum Gamma Glutamyl 
Transferase levels in cases presenting with acute coronary syndromes. 
2. To determine the possible association between raised GGT levels and 
different subsets of ACS. 
3. To determine the association between raised serum GGT levels and in-
hospital adverse cardiovascular outcomes. 
4. To determine the association between raised GGT levels and risk factors 
for acute coronary syndrome. 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
This study was done at Government Royapettah Hospital, Chennai 
between May 2013 to October 2013. The study was performed after procuring 
informed written consent from all the participants involved.  Clearance was 
obtained from the Ethical Committee of  Government Kilpauk Medical College 
& Hospital Chennai. 
STUDY DESIGN AND PATIENT SELECTION: 
This is a cross sectional, comparative study in which seventy five cases 
presenting as Acute Coronary Syndrome to the coronary care unit of our 
hospital were selected. 
INCLUSION CRITERIA 
All patients admitted with an episode of Acute Coronary Syndrome in the 
coronary care unit of Government Royapettah Hospital. 
EXCLUSION  CRITERIA 
1. History of any alcohol intake 
2. History of hepatobiliary disease 
3. Surgical conditions causing obstructive jaundice 
4. Alanine transaminase (ALT)>40U/IL 
5. Coarse liver echotexture on ultrasonography 
6. History of taking drugs such as barbiturates, phenytoin, anti tubercular 
drugs 
METHODOLOGY 
All patients presenting with acute coronary syndrome were included in 
the study. Gamma glutamyl tranferase levels were measured in all the 
patients using a standardized photometric method with the normal value 
noted as      0-45 IU/L. Blood samples were taken uniformly six hours from 
the time of presentation. Cases were divided into three subsets based on 
electrocardiographic and Troponin T measurement; 
1. ST elevation MI, 
2. Non ST elevation MI and  
3. Unstable angina.  
Patients were followed up for five days in the hospital from admission 
into CCU for in-hospital outcome. Major adverse cardiovascular events were 
recorded in the form of re-infarct, cardiogenic shock requiring inotropic 
support, ventricular arrythmias requiring cardioversion, pulmonary edema 
and cardiac death. Changes in GGT levels in ACS and its prognostic value 
on the development of MACE were studied. 
The following investigations were done in all the patients entering into the 
study: 
 Gamma glutamyl transferase levels 
 14 lead Electrocardiogram 
 2D echocardiography with doppler 
 Total cholesterol 
 LDL and HDL cholesterol 
 FBS and PPBS 
 Troponin T estimation 
 Liver function tests 
 Ultrasonography for liver echotexture 
 
STATISTICAL ANALYSIS 
Data was entered in Windows Excel format. Frequency tables and  measures of 
central tendency (mean) and measures of dispersion (Standard Deviation) were 
calculated by using the statictical package SPSS- 20.  Correlation was assessed 
using the chi-square test. 
 
 
 RESULTS AND OBSERVATIONS 
DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
GENDER AND CORRELATION WITH GGT 
46 patients out of the study population of 75 were male and 29 were female. 
 
 
Sex 
  
  
GGT 
Total 
  
P value 
Positive Negative 
Male 
  
  
Count 20 26 46  
 
 
 
 
 
 
 
0.201 
% within 
Sex 
43.5% 56.5% 100.0% 
Female 
  
  
Count 17 12 29 
% within 
Sex 
58.6% 41.4% 100.0% 
 Total Count 37 38 75 
% within 
Sex 
49.3% 50.7% 100.0% 
% within 
GGT 
100.0% 100.0% 100.0% 
Table 1- correlation between GGT and gender 
61% 
39% 
fig 1DISTRIBUTION OF GENDER IN THE 
STUDY 
MALE FEMALE 
20 out of 46 males had a positive value for GGT (43.5%). 17 out of 29 females 
were positive for GGT (54.1%).The p value was 0.201. There was no significant 
correlation between gender and GGT in this study. 
 
 
DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
DIABETIC STATUS AND CORRELATION WITH GGT 
 
    GGT Total P value 
    Positive 
Negativ
e   
Diabetes Yes Count 20 15 35  
 
 
 
0.206 
  
  
  % within 
Diabetes 
57.1% 42.9% 100.0% 
No Count 17 23 40 
  % within 
Diabetes 
42.5% 57.5% 100.0% 
Total Count 37 38 75 
  % within 
Diabetes 
49.3% 50.7% 100.0% 
Table 2-Correlation between GGT and diabetes 
35 patients out of 75 in the study population were diabetics and 40 non-
diabetics. Twenty patients out of the diabetic group were positive for GGT. 
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SEX 
fig 2-CORRELATION BETWEEN GENDER 
AND GGT 
GGT POSITIVE 
GGT NEGATIVE 
Pvalue was 0.206.There is no significant correlation between diabetic status and 
GGT levels in this study. 
 
DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
HYPERTENSIVE STATUS AND CORRELATION WITH GGT 
 
 
 
 
Out of the 75 subjects 36 were hypertensives. 24 out of 36 hypertensives were 
positive for GGT. P value is 0.004. There is significant correlation between 
hypertension and GGT. 
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DIABETIC STATUS 
fig 3-CORRELATION BETWEEN DIABETES AND GGT 
GGT POSITIVE 
GGT NEGATIVE 
   GGT Total P value 
    Positive Negative   
SHT 
  
  
  
  
Yes Count 24 12 36  
 
 
 
0.004 
  % within 
SHT 
66.7% 33.3% 100.0% 
No Count 13 26 39 
  % within 
SHT 
33.3% 66.7% 100.0% 
Total 
  
Count 37 38 75 
% within 
SHT 
49.3% 50.7% 100.0% 
Table 3- Correlation between GGT and hypertension 
  
DISTRIBUTION OF STUDY SUBJECTS BASED ON SMOKING 
STATUS AND CORRELATION WITH GGT 
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fig 4-CORRELATION BETWEEN HYPERTENSION 
AND GGT 
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   GGT Total 
P 
value 
    Positive 
Negativ
e   
 
 
 
 
 
0.300 
Smoking Yes Count 17 13 30 
  
  
  
  
  
  % within 
Smoking 
56.7% 43.3% 100.0% 
No Count 20 25 45 
  % within 
Smoking 44.4% 55.6% 100.0% 
Total Count 37 38 75 
  % within 
Smoking 
49.3% 50.7% 100.0% 
Table 4- Correlation between GGT and smoking1 
 30 subjects in the study population were chronic smokers. 17 of them turned 
out to be positive for GGT. The p value is 0.300. There is no significant 
correlation between smoking status and rise in GGT. 
 
 
DISTRIBUTION OF STUDY SUBJECTS BASED ON TYPE OF ACUTE 
CORONARY SYNDROME AND CORRELATION WITH GGT VALUES 
Table 5   GGT Total P value 
    Positive Negative   
Type of 
ACS 
STEMI Count 
23 7 30 
 
 
 
 
 
 
<0.001 
 
 
 
 
  
  
  
  
  
  
  
  
  % within 
Type of 
ACS 
76.7% 23.3% 100.0% 
NSTEMI Count 14 10 24 
  % within 
Type of 
ACS 
58.3% 41.7% 100.0% 
  % within 
GGT 
37.8% 26.3% 32.0% 
UA Count 0 21 21 
  % within 
Type of 
ACS 
.0% 100.0% 100.0% 
Total Count 37 38 75 
  % within  
ACS type 
49.3% 50.7% 100.0% 
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In our study of 75 patients 30 had ST elevation in their ecgs, 24 subjects 
suffered from NSTEMI and 21 patients had unstable angina.  
23 out of 30 patients with STEMI were positive for GGT. 14 out of 24 patients 
were positive for GGT while none of the unstable angina subset had a positive 
GGT value. P value is 0.001. Therefore there is a highly significant correlation 
between type of ACS and GGT levels with STEMI and NSTEMI showing 
positive values compared to unstable angina. 
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DISTRIBUTION OF SUBJECTS BASED ON TROP T POSITIVITY  
AND CORRELATION WITH  GGT 
 
 
 
 
 
 
 
 
In the study group of 75, people with Trop T positive were 54. Out of 54 
subjects, 37 of them were positive for GGT. P value is 0.001. It shows a highly 
significant correlation between Trop T positivity and GGT positivity. 
Figure 7- Correlation between GGT and TROP T 
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   GGT Total p value 
    Positive 
Negativ
e   
TROP T Positive Count 37 17 54  
 
 
 
 
 
 
<0.001 
  
  
  
  
  
  % within 
TROP T 
68.5% 31.5% 100.0% 
Negative Count 0 21 21 
  % within 
TROP T 
.0% 100.0% 100.0% 
Total Count 37 38 75 
  % within 
TROP T 
49.3% 50.7% 100.0% 
Table 6-correlation between GGT and TROP T 
DISTRIBUTION OF STUDY SUBJECTS BASED ON PRESENCE OR 
ABSENCE OF RWMA (REGIONAL WALL MOTION ABNORMALITY) 
ON ECHOCARDIOGRAPHY AND CORRELATION WITH GGT 
   GGT Total 
P 
VALUE 
    Positive Negative   
RWMA Yes Count 20 5 25  
 
 
 
 
<0.001 
  
  
  
  
  
  % within 
RWMA 
80.0% 20.0% 100.0% 
No Count 17 33 50 
  % within 
RWMA 
34.0% 66.0% 100.0% 
Total Count 37 38 75 
  % within 
RWMA 
49.3% 50.7% 100.0% 
Table 7-Correlation between GGT and RWMA 
Out of 75 study subjects 25 had demonstrable Regional wall motion 
abnormality of the ventricular wall on echocardiography. Out of this subset 20 
patients had positive GGT values accounting for 80%. The p value is 0.001. 
Therefore there is highly significant correlation between RWMA on 
echocardiography and GGT levels.  
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DISTRIBUTION OF STUDY SUBJECTS BASED ON PRESENCE OR 
ABSENCE OF LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND 
CORRELATION WITH GGT 
   GGT Total P value 
    
Positiv
e Negative   
LV Dys 
Function 
Yes Count 
20 6 26 
 
 
 
 
 
 
<0.001 
  
  
  
  
  
  % within LV Dys 
Function 
76.9% 23.1% 100.0% 
No Count 17 32 49 
  % within LV Dys 
Function 
34.7% 65.3% 100.0% 
Total Count 37 38 75 
  % within LV Dys  49.3% 50.7% 100.0% 
Table 8- Correlation between GGT and LV dysfunction 
  
26 out 75 study subjects had systolic LV dysfunction on echocardiography as 
evidenced by an ejection fraction on echocardiography <50%. 20 patients out of 
that subset had a positive GGT value. The p value is <0.001.  In this study there 
is a significant correlation between presence of LV dysfunction and high GGT 
values. 
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 DISTRIBUTION OF STUDY SUBJECTS BASED ON EPISODES OF 
MAJOR ADVERSE CARDIOVASCULAR EVENTS 
   GGT Total P value 
    Positive 
Negativ
e   
MACE Yes Count 18 0 18  
 
 
 
<0.001 
  
  
  
  
  
  % 
within 
MACE 
100.0% .0% 100.0% 
No Count 19 38 57 
  % 
within 
MACE 
33.3% 66.7% 100.0% 
Total Count 37 38 75 
  % 
within 
MACE 
49.3% 50.7% 100.0% 
Table 9- Correlation between GGT and MACE 
 
 
 
 
Out of the study population of 75, 18 subjects suffered from major adverse 
cardiovascular events (MACE) within their five day in-hospital period in the 
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33% 
FIG  10-DISTRIBUTION OF MACE IN STUDY 
POPULATION(N=18) 
form of one of the following; reinfarct, ventricular tachycardia or fibrillation 
requiring defibrillation, cardiogenic shock requiring inotropic support, death. 
All 18 patients had significantly positive GGT values. P value is <0.001. There 
is a significant correlation between incidence of MACE and GGT levels. 
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MACE 
 CORRELATION BETWEEN MEAN GGT AND MACE  
 MACE N Mean Std. Deviation P value 
GGT(IU/
L) 
Yes 
18 90.22 7.818 
<0.001 
No 
57 46.44 19.363 
Table 10 Correlation between GGT and MACE 
 
 
 
 
 
18 subjects suffered from one of the major cardiovascular adverse events. The 
mean value for these patients is 90.22. The mean GGT value for patients 
without MACE is a significantly less 46.44. The p value is significant with 
0.001. 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
YES NO 
M
EA
N
 G
G
T
 
PRESENCE OF MACE 
FIG 13-MEAN GGT 
 CORRELATIONOF OTHER VARIABLES WITH GGT 
 
 
 
 
 
 
 
        
 
 
 
                                                                                                      
  There is no significant correlation between increasing age and GGT positivity 
in this study. The p value is 0.799. 
In comparing the total cholesterol levels with GGT, the p value is significant 
<0.001. therefore there is  a highly significant correlation between total 
cholesterol and GGT. 
   
GGT(IU/
L) 
Age in years Pearson 
Correlation 
-.030 
p value 
.799 
Cholesterol Pearson 
Correlation 
.523(**) 
p value <0.001 
 
LDL Pearson 
Correlation 
.484(**) 
p value <0.001 
 
HDL Pearson 
Correlation 
.155 
p value 
0.183 
BMI Pearson 
Correlation 
.228(*) 
p value 
0.049 
Table 11- Correlation of other variables with GGT 
                                                                                                                                                                      
In comparing LDL cholesterol levels and GGT, the p value is <0.001. 
Therefore there is a highly significant correlation between LDL levels and 
GGT positivity. 
In comparing HDL levels and GGT, the p value is 0.183. Therefore there is no 
significant correlation between HDL levels and GGT positivity. 
In comparing BMI of the study subjects with GGT, the p value is 0.049. 
Therefore there is moderate correlation between high BMI values and 
GGT positivity. 
CORRELATION OF GGT VALUES IN THREE TYPES OF ACS BY 
ANOVA TEST 
 N Mean Std. Deviation 
P value 
STEMI 
30 74.03 23.348 
 
 
 
<0.001** 
NSTEMI 
24 54.88 23.058 
UA 
21 34.90 7.609 
Table 12- Correlation of GGT with types of ACS 
  
  
 
ANOVA test was used to look for correlation between the three types of ACS 
with their respective mean GGT values. The mean GGT values for the STEMI, 
NSTEMI and UNSTABLE ANGINA subsets were respectively 74.03, 54.88 
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FIG 15-MEAN GGT IN DIFFERENT TYPES OF ACS 
and 34.90 respectively. The p value was significant for this test,<0.001. 
Therefore the difference in GGT values in the three subsets was statistically 
relevant. 
POST-HOC TEST 
(I) Type of ACS (J) Type of ACS 
Mean 
Difference (I-
J) Std. Error p value 
          
STEMI NSTEMI 19.16(*) 5.515 0.002 
  UA 39.13(*) 5.729 <0.001 
NSTEMI STEMI -19.16(*) 5.515 0.002 
  UA 19.97(*) 6.017 0.004 
UA STEMI -39.13(*) 5.729 <0.001 
  NSTEMI -19.97(*) 6.017 0.004 
TABLE 13-GGT variation in different types of ACS 
A post hoc test was calculated to compare each type of ACS with the other two 
types and statistically correlate the difference between them. The p value was 
highly significant while comparing the difference in GGT levels in STEMI with 
both NSTEMI and UNSTABLE ANGINA. Likewise the p value was significant 
while comparing NSTEMI and unstable angina with the other two subsets. 
 
 
 
 
 DISCUSSION 
 
This study is a single centre cross sectional hospital based study done at 
Government Royapettah Hospital, Chennai. Our study population included 
patients admitted to the Intensive Coronary Care Unit of our hospital with Acute 
Coronary Syndrome during the period from May 2013 to October 2013. All the 
cases were divided into three subsets; ST elevation MI, non ST elevation MI 
and unstable angina based on electrocardiographic and TroponinT 
measurements. Baseline gamma glutamyl tranferase levels were measured by a 
standardized method for all the patients. All the subjects were observed for the 
first five days of their hospital stay for episodes of re-infarcts, ventricular 
arrythmias requiring defibrillation, cardiogenic shock requiring inotropic 
support, pulmonary edema and death. Multiple parameters including traditional 
risk factors of coronary artery disease as well as its complications were 
compared to GGT to look for correlation. 
Age and Sex 
In our study majority of patients were males (61%) and females accounted for 
39% with a male: female ratio of approximately 3:2. 43.5% of males and 54.1% 
females had an elevated GGT value. However there was no significant 
correlation between gender and GGT in this study. 
The age group of our patients ranged from 37 to 84 and the mean age was 60.3 
with peak incidence in the fifth and sixth decades. In this study there was no 
statistical correlation between age and GGT. 
In the study conducted by Emiroglu MY et al
129
 comparing CRP and GGT, 
published in the North American Journal of Medical Sciences in 2010, the 
majority of the patients in each subset of ACS were males and male sex showed 
a positive correlation with GGT values. However the same study showed no 
correlation between age and GGT. 
In the study conducted by Alexander  M Strasak et al
143
, the age of participants 
significantly modified the relation between GGT change and CVD mortality, 
with markedly stronger associations to be observable for younger individuals. 
DIABETES 
Out of the 35 diabetics in the study group 20 cases were positive for GGT. Our 
study showed no significant correlation between presence of diabetes mellitus 
and GGT positivity with a p value of 0.206. 
In the study conducted by Emiroglu MY et al
129
, no correlation between 
diabetes mellitus and GGT levels was observed. 
In the study conducted by Wannamathee G et al
4
 GGT values were positively 
correlated with diabetes mellitus. 
 
SYSTEMIC HYPERTENSION 
24 out of the 36 hypertensives in our study were positive for GGT. It showed a 
positive correlation between hypertensive status and GGT with a p value of 
0.004.  
In the study conducted by Emiroglu et al
129
 there was no correlation between 
hypertensive status and GGT 
In the study conducted by Wannamathee G et al
4
 GGT values were positively 
correlated with systemic hypertension.
 
 
SMOKING AND GGT 
17 out of the 30 smokers in the study group were positive for GGT. Since the p 
value was 0.3, there was found to be no statistically significant correlation 
between smoking and GGT. 
In the study conducted by Emiroglu et al
129
 there was no correlation between 
hypertensive status and GGT. 
 
TYPE OF ACS AND GGT 
In our study of 75 patients 30 had ST elevation in their ecgs, 24 subjects 
suffered from NSTEMI and 21 patients had unstable angina.  
23 out of 30 patients with STEMI were positive for GGT. 14 out of 24 patients 
were positive for GGT while none of the unstable angina subset had a positive 
GGT value. The mean GGT value for STEMI patients was 74.03 IU/L. The 
mean value for NSTEMI and unstable angina were respectively 54.88IU/L and 
34.90IU/L. In comparing the correlation between types of ACS and level of 
GGT p value was significant <0.001. The mean value in unstable angina is 
within normal limits. Although the mean values in the other two subsets were 
elevated, the mean GGT in the STEMI subset was significantly higher than the 
NSTEMI subset. This reveals that GGT shows promise as a sensitive diagnostic 
marker of STEMI. 
The study conducted by Emiroglu et al
129
 showed positive correlation between 
types of ACS and GGT. However there was no correlation in this study between 
STEMI subset and NSTEMI subset. Mean value of GGT in unstable angina 
subset was similar to that of control group. 
In the study conducted by Dogan A et al
144
 mean GGT level was higher in ACS 
group than control group (32 vs. 16 U/l, P=0.001). 
GGT values of cases presenting with MI were higher in comparison to cases 
with stable angina according to the study performed by Demircan S et al 
(p<0.002) 
 
TROP T AND GGT 
Out of the 54 cases in the study that were positive for Trop T, 37 were positive 
for GGT. There was proven to be a significant correlation between Trop T and 
GGT. Further, GGT behaves similar to Trop T in that it is not elevated in any of 
the cases in the unstable angina subset. 
In the study conducted by Emiroglu et al
129
 positive correlation was seen 
between Trop T and GGT with a p value of 0.001. 
 
LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND GGT 
20 out of the 26 patients who were diagnosed to have systolic dysfunction on 
echocardiography were positive for GGT. There was a statistically significant 
correlation between GGT and LV dysfunction. Therefore high GGT values at 
presentation can assist in anticipating the complications of LV failure in patients 
presenting with ACS. 
MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) 
A total of 18 patients suffered from MACE in the study group. Two patients 
suffered from re-infarct, four patients died in the hospital, five patients had to be 
on dopamine support for cardiogenic shock. One patient went in for 
hemodynamically unstable ventricular tachycardia and six cases suffered from 
acute pulmonary edema. All the patients who suffered from MACE had an 
elevated GGT and the p value was highly significant. 
The mean GGT value of the MACE subset was 90.22+7.818 and mean GGT of 
the non-MACE group was 46.44+19.363. Comparing the two groups too, the p 
value was highly significant. Hence our study shows that an elevated GGT level 
at presentation can anticipate adverse cardiovascular outcomes in ACS patients. 
GGT therefore can be an important tool in prognosticating MI patients based on 
risk. 
 In the study conducted by Dogan A et al
144
 which included 237 cases, MACE-
free survival was slightly poor in ACS patients with upper GGT tertile 
compared with those with lower GGT tertile (77 vs. 97%, P=0.06) even though 
p value was not significant. 
GGT values were elevated more than normal in the subset of patients with 
significant complications, in the study performed by Ulus T et al
145
 
Asma Kamal et al
146 
 found that GGT values were higher than normal in the 36 
subjects who suffered adverse cardiovascular events and a sizeable percentage 
of this subset suffered cardiac death, with a p value<0.001) 
OTHER PARAMETERS 
Other parameters that were compared were total cholesterol levels, LDL levels, 
HDL levels and body mass index. 
Comparing the total cholesterol levels and GGT, the p value was not significant. 
There is no correlation between total cholesterol and GGT in this study. 
In the study conducted by Emiroglu et al
129
 there was no correlation between 
total cholesterol and GGT. 
In the study conducted by Wannamathee G et al
4
 GGT values were positively 
correlated with total cholesterol. 
Comparing LDL and GGT, the p value was <0.001. Therefore in our study, 
cases with higher LDL values were prone for GGT positivity. This is 
compatible with the recent studies which reveal GGT as playing an important 
role in LDL oxidation, which in turn is a hallmark of atherosclerotic heart 
disease. 
In the study conducted by Emiroglu et al
129
 no correlation between LDL 
cholesterol and GGT was observed. 
In the study conducted by Wannamathee G et al
4
 GGT values were positively 
correlated with LDL cholesterol. 
 
HDL and BMI had no statistical relationship with GGT in our study. 
In the study conducted by Emiroglu et al
129
 there was no correlation between 
HDL cholesterol, BMI and GGT 
 A post hoc analysis was done to assess the strength of GGT in predicting 
different types of acute coronary syndromes. The p value was highly significant 
while comparing GGT levels of one subset with each of the other subsets. This 
once again proves the utility of GGT in differentiating different types of ACS. 
 
 
                                            
 
                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 CONCLUSIONS 
 
 Gamma glutamyl transferase levels are significantly elevated above 
normal in patients presenting with acute coronary syndrome. 
 GGT levels were independently correlated with STEMI and NSTEMI but 
had no correlation with unstable angina. 
 There is a significant correlation between GGT levels and incidence of  
left ventricular systolic LV dysfunction 
 The mean value of GGT was significantly elevated in patients who 
suffered from major adverse cardiovascular events. Patients with 
significantly elevated GGT values may, in future, be referred for early 
invasive revascularization procedures like PCI/CABG. 
 In conclusion, as concerns ischemic heart disease, GGT assay seems to 
have the features of a good prognostic marker with optimal sensitivity of 
the diagnostic assay and it helps improve our ability to predict adverse 
events in CAD. Further its prognostic impact can be utilized in risk 
stratification and the need for urgent therapeutic intervention. 
  
 
                           
 LIMITATIONS OF THE STUDY 
1. The sample size of the study (75) was relatively small. A larger number 
would have strengthened our understanding of the correlation between 
the studied parameters. 
2. There was no control group in the study. Even though the Unstable 
Angina subset acted as a control group in view of its almost normal GGT 
distribution, a subset containing people with non anginal chest pain 
would have given a clearer picture of the discriminatory power of GGT. 
3. There is no way to know whether some subjects already had elevated 
GGT values or if the rise was linked to the ischemic event. Only further 
long term prospective studies will clearly elucidate this cause and effect 
dilemma. 
 
 
 
 
 
 
           
THERAPEUTIC IMPLICATIONS 
Acute coronary syndrome is one of the most common presentations to the 
medical casualty. Despite major advances in the diagnosis and management of 
this serious disorder, there is still much scope for improvement in reducing 
mortality and morbidity. Further, around 2%-3% of myocardial infarction cases 
are still missed in emergency departments leading to unforeseen fatalities.
1  
In the study done in our hospital, GGT was significantly elevated in patients 
presenting with ACS. In addition, the mean GGT values of the three different 
groups of ACS were significantly different from one another. In comparing the 
correlation between types of ACS and level of GGT p value was <0.001. 
Therefore GGT may have a role in diagnosing cases of myocardial infarction 
especially in the presence of a non-diagnostic ECG. This will help in preventing 
MI cases to be missed in the ED. In addition to its diagnostic role in MI, GGT 
also has a discriminatory capacity to differentiate between STEMI, NSTEMI 
and UA. GGT can hence be an important laboratory tool alongside Troponin T 
and the electrocardiogram in the categorization of MI.  
In our study, the mean GGT value of the subset having cardiovascular 
complications was 90.22+7.818 and mean GGT of the non-MACE group was 
46.44+19.363. Comparing the two groups too, the p value was highly 
significant. Hence our study shows that an elevated GGT level at presentation 
can be reflective of impending adverse effects in ACS patients. Studies 
worldwide have shown that high risk MI patients fare better when treated with 
invasive revascularization rather than conservative measures. This has wide 
ranging policy implications in the form of early referral to a higher centre that is 
equipped with PCI facilities. GGT, keeping in mind its reduced cost compared 
to Troponins, can therefore be an important tool in prognosticating MI patients 
based on risk. 
I would like to suggest that a high volume multi-centre study is reasonable to 
further study this enzyme and its merits in the management of myocardial 
infarction. 
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ABBREVIATIONS 
ACS- acute coronary syndrome 
CAD- coronary artery disease 
CVD- cardiovascular disease 
DALY- disability adjusted life years 
ATHD- atherosclerotic heart disease 
GGT- gamma glutamyl transferase 
CK- creatine kinase 
LVD- left ventricular dysfunction 
RWMA- regional wall motion abnormality 
SHT- systemic hypertension 
DM- diabetes mellitus 
STEMI- ST elevation myocardial infarction 
NSTEMI- non ST elevation myocardial infarction 
UA- unstable angina 
LDL- low density lipoprotein 
HDL- high density lipoprotein 
TC- total cholesterol 
BMI- body mass index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
QUESTIONNAIRE PROFORMA 
ASSOCIATION OF RAISED GAMMA GLUTAMYL TRANSFERASE LEVELS IN 
PATIENTS WITH ACUTE CORONARY SYNDROME AND CORRELATION WITH 
THEIR IN-HOSPITAL OUTCOME 
 
NAME: 
AGE: 
SEX: 
ADDRESS: 
TELEPHONE NUMBER: 
OCCUPATION: 
HISTORY OF DIABETES MELLITUS AND SYSTEMIC HYPERTENSION 
DRUG HISTORY: 
Phenytoin 
Barbiturates 
Anti tubercular drugs 
Carbamazepine 
Anabolic steroids 
Psychotropic drugs 
PERSONAL HISTORY: 
Alcoholism 
Smoker  
HISTORY:  h/o of chest pain 
h/o of previous IHD 
h/o systemic hypertension 
h/o  CKD 
h/o  surgeries 
h/o alcohol consumption /drinking pattern 
h/o smoking (in pack years) 
h/o jaundice, acsites 
 
 
 
 
EXAMINATION 
 
 
HEIGHT: 
WEIGHT: 
BMI: 
PULSE RATE: 
 
PERIPHERAL PULSES EXAMINATION: 
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GENERAL EXAMINATION: 
  
SYSTEM WISE EXAMINATION: 
CVS: 
RS: 
P/A: 
CNS: 
 
 
INVESTIGATIONS 
Complete blood count: 
Hb: 
ESR: 
TC: 
DC: 
Chest Xray : 
 
 
 
 
Serum Bilirubin: 
ALT/AST : 
ALP:  
 
  
 
 
 
 
 
 
 
 
 
MACE NUMBER DAY 
1.CARDIOGENIC SHOCK   
2.PULMONARY EDEMA   
3.RE-INFARCT   
4.VENTRICULAR TACHY   
5.DEATH   
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1.FASTING PLASMA GLUCOSE (mg/dl) 
 
 
 
2.POST PRANDIAL PLASMA 
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6.FASTING TOTAL CHOLESTEROL 
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8.LDL  
9.HDL  
10.GGT  
 
 
12.ECG  
13.ECHOCARDIOGRAPHY  
14.TROPONIN T  
  
  
 
 
